Skip to main content

It's Not About Plastics Anymore


We’ve got one word for you: biochips. According to a new Frost & Sullivan report, the global market for microarrays, microfluidic devices, and other biochips will see annual growth of 65 percent and reach $3.3 billion by 2004.

More than 100 companies have already seen the microarray light, the report says. F&S predicts that segment’s revenues will hit $2.6 billion in 2004, up from estimates of $874 million this year and $232 million in 1999. The report suggests that the microarray market will be marked by ongoing patent disputes, consolidation, a trend toward higher density arrays, and more labs investing in homemade microarrays.

The microfluidics segment, which is said to be just starting, will grow to $395 million by 2004 from $17 million in 1999 and $77 million this year, according to the report. It goes on to note the spurt of alliances emerging between companies in this sector and liquid handling companies.

Other types of chips will grow too, the report says, with estimates at $311 million by 2004, up from $81 million this year. Notable growth is forecast for biochips using bioelectric detection.

Long term, F&S predicts that the sector could eventually see even more growth. “If diagnostic tests (human or otherwise) using biochips become widespread, the market for such products could reach the tens of billions by 2010,” according to the report.

— Marian Moser Jones

The Scan

Rise of B.1.617.2 in the UK

According to the Guardian, UK officials expect the B.1.617.2 variant to soon be the dominant version of SARS-CoV-2 there.

Anne Schuchat to Retire

Anne Schuchat is retiring after more than 30 years at the US Centers for Disease Control and Prevention, Politico reports.

US to Share More Vaccines

CNN reports that the US will share 20 million doses of the Moderna, Pfizer, and Johnson & Johnson SARS-CoV-2 vaccines with other countries.

PNAS Papers on Gene Therapy Platform, Aspergillus Metabolome, Undernutrition Model Microbiome

In PNAS this week: approach to deliver protein-based treatments to cells, pan-secondary metabolome of Aspergillus, and more.